Polarean Imaging seeks FDA priority review for NDA submission

Over 1400 Total Lots Up For Auction at Six Locations - MD 06/16, UT 06/18, France 06/21, PA 06/22, UT 06/24, CA 06/25

Polarean Imaging seeks FDA priority review for NDA submission

Press releases may be edited for formatting or style | October 08, 2020 MRI
DURHAM, N.C. -- (BUSINESS WIRE) -- Oct 7, 2020 -- Polarean Imaging plc (AIM: POLX), the medical‑imaging technology company, with an investigational drug‑device combination product for magnetic resonance imaging (MRI), announces its submission of a New Drug Application (“NDA”) and request for priority review to the US Food and Drug Administration (“FDA”) for hyperpolarised 129 Xenon gas used to evaluate pulmonary function and to visualise the lung using MRI.

The submission of the NDA follows the Company’s successful completion of two Phase III clinical trials (the “Clinical Trials”) which demonstrated effective measurement of regional lung ventilation. In the Clinical Trials, Polarean’s 129 Xenon gas MRI was used to measure regional pulmonary function in patients with a wide variety of underlying lung diseases who were being evaluated for possible lung resection or lung transplant surgery. As detailed in the Company’s announcement of 29 January 2020, both Clinical Trials met their primary endpoints, showing pre-defined equivalence of hyperpolarised 129 Xenon Gas MRI to an approved comparator, 133 Xenon Scintigraphy, and displayed a benign safety profile.

129 Xenon, when polarised in Polarean’s proprietary drug-device system, permits functional, regional and quantitative imaging of the lungs using MRI, without the risk of exposing patients to ionising radiation. The polarised 129 Xenon is administered as an inhaled gas that is given to patients in a 10 second breath-hold MRI procedure.

Two Medical Facility Online Auctions! Call 314-429-4112

Midwest Hand Surgery Auction Closing 5/26 at 8PM. Hologic Fluoroscan Insight-FD Mini C-Arm, Nuvo Dual-Lamp Surgical Lighting System W/Control Panel, Ritter M11 Ultraclave Automatic Sterilizer & More! 2 Day Women's Treatment Center Auction Coming Soon!

Commenting on the submission, Richard Hullihen, CEO of Polarean, said :“The NDA submission of 129 Xenon gas MRI as a drug-device combination represents another key regulatory milestone for our Company. I am delighted with the performance of Polarean’s team, who have worked tirelessly to achieve this important goal, and would also like to thank the institutions, clinicians and patients who took part in the studies that have formed part of this NDA.

“More than 30 million Americans suffer from a chronic lung disease and we see a significant unmet need for non-invasive, quantitative and cost-effective image-based diagnostic technology without exposing patients to ionising radiation. We look forward to working with the FDA to address this unmet need.”

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

About Polarean
The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, medical drug-device combination companies operating in the high-resolution medical imaging market.

You Must Be Logged In To Post A Comment